NASDAQ$RYTM
Rhythm Pharmaceuticals Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results and provided a business update.
Rhythm Pharmaceuticals reported their Q4 2021 financial results, highlighting the commercial availability of IMCIVREE and progress in clinical development and regulatory efforts.
- IMCIVREE fourth quarter sales were $1.8M.
- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022.
- Enrollment completed in Phase 2 trial evaluating setmelanotide in patients with hypothalamic obesity.
- A potential U.S. approval for IMCIVREE in BBS and Alström syndrome now set for June.
Headline financials
Revenue & EPS history
Rhythm Pharmaceuticals · Revenue · Quarterly
$1.82M
Forward guidance
Rhythm expects that its existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements into at least the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+3.1%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+5.4%
Avg return
30 days after
53%
18 / 34 earnings
Positive
+40.8%
Q2 2022
Best reaction
-15.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.2% | +10.3% | +2.5% | |
| Q4 2025 | -0.9% | -9.7% | -23.5% | |
| Q3 2025 | -7.7% | -11.8% | -7.1% | |
| Q1 2025 | +2.9% | -6.0% | +8.6% | |
| Q4 2024 | +4.5% | +2.7% | +7.4% | |
| Q3 2024 | +18.2% | +27.1% | +9.1% | |
| Q2 2024 | -1.1% | +2.8% | +9.6% | |
| Q1 2024 | -11.3% | -10.8% | -9.6% | |
| Q4 2023 | -7.5% | -5.7% | -16.9% | |
| Q3 2023 | +1.2% | +5.1% | +40.3% | |
| Q2 2023 | +36.3% | +37.0% | +45.8% | |
| Q1 2023 | -8.4% | -17.4% | -15.0% | |
| Q4 2022 | +0.1% | -9.8% | -26.6% | |
| Q3 2022 | -2.5% | +15.5% | +15.7% | |
| Q2 2022 | +40.8% | +62.6% | +103.5% | |
| Q1 2022 | -12.5% | -32.1% | -46.0% | |
| Q4 2021 | +21.3% | +21.7% | +51.2% | |
| Q3 2021 | +14.4% | +14.9% | -24.0% | |
| Q2 2021 | -15.7% | -17.5% | -22.1% | |
| Q1 2021 | -0.1% | +2.6% | -10.5% | |
| Q4 2020 | +3.2% | +0.2% | -17.9% | |
| Q3 2020 | +8.8% | +7.9% | +51.2% | |
| Q2 2020 | -2.4% | -1.8% | +55.2% | |
| Q1 2020 | +7.1% | +8.7% | +10.9% | |
| Q4 2019 | +3.0% | -5.4% | -22.1% | |
| Q3 2019 | +0.6% | -1.3% | +5.3% | |
| Q2 2019 | -4.7% | -2.9% | +11.7% | |
| Q1 2019 | -0.7% | -1.0% | -2.4% | |
| Q4 2018 | +5.8% | +8.2% | +1.6% | |
| Q3 2018 | -12.3% | -15.3% | -13.1% | |
| Q2 2018 | -1.3% | -2.8% | -5.9% | |
| Q1 2018 | +17.8% | +21.2% | +29.9% | |
| Q4 2017 | +6.9% | -16.3% | -24.0% | |
| Q3 2017 | -5.7% | +1.3% | +10.1% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro